



Thor Medical strengthens executive team to realise leadership ambitions in targeted alpha therapies

18.11.2025 07:30:00 CET | Thor Medical ASA | Non-regulatory press releases

Oslo, 18 November 2025 – Thor Medical ASA today announces the appointment of Therese Kvehaugen and Mathias Nilsen Reiervang to the executive management team, two key additions as the company accelerates its growth journey to become a global leader in the sustainable supply of alpha isotopes for targeted cancer therapies.

Therese Kvehaugen will join Thor Medical as Executive Vice President, Human Resources, effective January 12, 2026, while Mathias Nilsen Reiervang will take on the role of Head of Communications and Corporate Affairs no later than February 1, 2026. Both will report directly to CEO Jasper Kurth and become members of the company's executive management team.

"We have high ambitions at Thor Medical and are building an organization capable of driving meaningful impact for cancer patients, customers and partners, and society at large. Strengthening our leadership team with exceptional people like Therese and Mathias is an important step on that journey," said Jasper Kurth, CEO of Thor Medical.

"Mathias combines strategic communications expertise with a strong understanding of advanced technology and industrial innovation, while Therese brings deep international HR experience from the biotechnology industry and a proven ability to scale high-performing, advanced organizations. Together, they will help transition Thor Medical from a pioneering phase to a key industrial-scale supplier in targeted cancer therapies," Kurth added.

Therese Kvehaugen joins Thor Medical from Timbr, a strategic HR advisory having served as CEO. Prior to that, she served as Head of HR at Nykode Therapeutics and she spent several years with Alnylam Pharmaceuticals in Switzerland, helping the company grow from a small pre-commercial biotech to a global Ribonucleic Acid therapeutics leader. Earlier in her career, she held HR leadership roles with Rambøll, Biogen and Franke.

Mathias Nilsen Reiervang brings extensive experience in communications, corporate affairs, and strategy from leadership roles in the green industry and energy sector at Vow Green Metals, Aker Horizons, and Hafslund. He also has a background as a journalist with leading Norwegian media, including TV 2, Dagens Næringsliv, and Verdens Gang, as well as experience from management consulting.

CONTACTS

Jasper Kurth, CEO, Thor Medical ASA, jasper.kurth@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'. To learn more, [visit www.thormedical.com](https://www.thormedical.com) - <https://www.thormedical.com>.

Attachments

- [Download announcement as PDF.pdf](#)